The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...

University of Florida scientists have engineered an experimental mRNA vaccine that stimulates the immune system to combat tumors in conjunc...

If market volatility is worrying you, just consider three things. An earnings season is set to start; valuations are not cheap; and last, b...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...

There are earnings seasons and their earnings seasons. While every earnings season is important, some are more important than others as the...

Nuvama has downgraded IndusInd Bank to "Reduce" citing concerns over internal derivative trades and management changes, while Antique remai...

Investors with high exposure to mid-caps should start planning for Q3 earnings and how the stocks in their portfolio will react to them. So...

Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic nasopharyngeal carcinoma ...

Dr Reddy's Laboratories launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer, in India. This d...

Dr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma ...

Dr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (N...

The reason for the popularity of PPIs among doctors and patients is not tough to gauge. With unhealthy lifestyles and dietary habits, acidi...

The USFDA approval paves the way for Glenmark's subsidiary Glenmark Specialty to proceed with a Phase 1/2, first-in-human, clinical study o...

Immunotherapy should be given as early as possible to achieve a lasting remission of the disease.

The Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to ...

Curis has agreed to make payments of up to $52.5 million per programme including $42.5 million for approval and commercial milestones,